Nordic Nanovector - Fundamentale forhold 2019 (NANO)

[anon21766851]

Tenker ASCO med ettårsdata på hele popula

Tidligere prioriterte Nano ASH og AACR, ikke ASCO.

Stemmer det, Lugano annenhvert år sant? Og den er i år ser jeg. 18-22 juni.

Hadde fått det for meg at det ikke var i år.

[TekBot]

20/02-2019 12:01:00: (NANO, NANOO.ST) Nordic Nanovector ASA: Invitation to Fourth Quarter and Full Year 2018 Results Presentation and Webcast

Oslo, Norway, 20 February 2019

Nordic Nanovector ASA (OSE: NANO) announces that it will report its fourth quarter and full year 2018 results on Wednesday, 27 February 2019.
…

Vis børsmeldingen

A presentation by Nordic Nanovector’s senior management team will take place at 8:30 am CET at:

Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo

Meeting Room: AKER

The presentation will be recorded as a webcast and will be available at www.nordicnanovector.com in the section: Investors & Media

The results report and the presentation will be available at www.nordicnanovector.com in the section: Investors & Media/Reports and Presentation/Interim Reports/2018 from 7:00 am CET the same day.

For further information, please contact: 

IR enquiries

Malene Brondberg, VP Investor Relations and Corporate Communications

Cell: +44 7561 431 762

Email: ir@nordicnanovector.com

Media Enquiries

Mark Swallow/David Dible (Citigate Dewe Rogerson)

Tel: +44 207 638 9571

Email:  nordicnanovector@citigatedewerogerson.com

About Nordic Nanovector: 

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers.

Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with substantial unmet medical need,

representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.

Further information can be found at www.nordicnanovector.com.

This information is subject to a duty of disclosure pursuant to Sections 4-2 and 5-12 of the Securities Trading Act. 

 

http://www.netfonds.no/quotes/release.php?id=20190220.Cision.20190220:BIT:3213:0

[anon21766851]

20/02-2019 12:01:00: (NANO, NANOO.ST) Nordic Nanovector ASA: Invitation to Fourth Quarter and Full Year 2018 Results Presentation and Webcast

Oslo, Norway, 20 February 2019

Nordic Nanovector ASA (OSE: NANO) announces that it will report its fourth quarter and full year 2018 results on Wednesday, 27 February 2019.
…

Vis børsmeldingen

A presentation by Nordic Nanovector’s senior management team will take place at 8:30 am CET at:

Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo

Meeting Room: AKER

The presentation will be recorded as a webcast and will be available at www.nordicnanovector.com in the section: Investors & Media

The results report and the presentation will be available at www.nordicnanovector.com in the section: Investors & Media/Reports and Presentation/Interim Reports/2018 from 7:00 am CET the same day.

For further information, please contact: 

IR enquiries

Malene Brondberg, VP Investor Relations and Corporate Communications

Cell: +44 7561 431 762

Email: ir@nordicnanovector.com

Media Enquiries

Mark Swallow/David Dible (Citigate Dewe Rogerson)

Tel: +44 207 638 9571

Email:  nordicnanovector@citigatedewerogerson.com

About Nordic Nanovector: 

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers.

Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with substantial unmet medical need,

representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.

Further information can be found at www.nordicnanovector.com.

This information is subject to a duty of disclosure pursuant to Sections 4-2 and 5-12 of the Securities Trading Act. 

 

http://www.netfonds.no/quotes/release.php?id=20190220.Cision.20190220:BIT:3213:0

[InVivo]

Stemmer det, Lugano annenhvert år sant? Og den er i år ser jeg. 18-22 juni.

Husker Lugano i 2017, ble en katastrofe for Nano. Lurer på om det var noen urealistiske forventninger rundt arm 4 som ikke ble innfridd.

[Fornybar]

Costa hypet opp Lugano som “our biggest conference yet”

[TekBot]

20/02-2019 14:07:22: (NANO, NANOO.ST) Nordic Nanovector ASA: Prospectus approved and Repair Offering

Oslo, Norway, 20 February 2019

Reference is made to the stock exchange announcement on 18 February 2019 where Nordic Nanovector ASA (the “Company”) announced that the extraordinary general meeting of the Company had granted the Board of Directors an authorisation to increase the share capital of the Company in connection with a repair offering of up to 777,777 new shares (the “Offer Shares”), each at a par value of NOK 0.20 at a subscription price of NOK 45.00 per Offer Share (the “Repair Offering”).
…

Vis børsmeldingen

The Financial Supervisory Authority of Norway has reviewed and approved the Company’s prospectus regarding the offering and listing of the Offer Shares (the “Prospectus”).

In connection with the Repair Offering, non-transferable subscription rights (the “Subscription Rights”) will be granted to shareholders of the Company as of 24 January 2019, as registered in the Norwegian Central Securities Depositary (the “VPS”) on 28 January 2019 (the “Record Date”), who did not participate in the private placement of 4,943,094 new shares in the company that were issued on 30 January 2019 (the “Private Placement”), and who are not resident in a jurisdiction where such offering would be unlawful, or would (in jurisdictions other than Norway) require any prospectus filing, registration or similar action (the “Eligible Shareholders”).

Each Eligible Shareholder will be granted 1 (one) non-transferable Subscription Right for each 46 existing shares registered as held by such Eligible Shareholder at the Record Date. The number of Subscription Rights granted to each Eligible Shareholder will be rounded down to the nearest whole Subscription Right. Each Subscription Right gives the right to subscribe for, and be allocated, one Offer Share in the Repair Offering. Over-subscription and subscription without Subscription Rights will be permitted; however there can be no assurance that Offer Shares will be allocated for such subscriptions.

The Subscription Period will begin on 21 February 2019 at 09.00 CET and end on 6 March 2019 at 16:30 CET (the “Subscription Period”). Subscription Rights that are not used to subscribe for Offer Shares before the expiry of the Subscription Period will have no value and will lapse without compensation to the holder.

Due Date for payment of the Offer Shares is 8 March 2019. Subject to timely payment of the Offer Shares subscribed for and allocated in the Repair Offering, the issuance of the Offer Shares pertaining to the Repair Offering is expected to be completed on or about 12 March 2019. The Offer Shares are expected to be delivered to the subscribers and commence trading on the Oslo Stock Exchange on the same day.

DNB Markets, a part of DNB Bank ASA, is acting as manager for the Repair Offering. Advokatfirmaet Wiersholm is acting as legal advisor to the Company. 

The Prospectus, including the subscription form, is attached to this notice and will also be available today at www.nordicnanovector.com, and on 21 February 2019 at www.dnb.no/emisjoner. The Prospectus, including the subscription form, will also be available at the offices of the Company and DNB Markets from the same dates. 

Subscriptions may be made by duly completing and delivering the subscription form, in accordance with the terms and conditions set out in the Prospects.  

Norwegian investors with a VPS account can in addition subscribe for Offer Shares online at www.dnb.no/emisjoner (http://www.dnb.no/emisjoner%20from%20[20) from 21 February 2019. 

For further information, please contact:

Malene Brondberg, VP Investor Relations and Corporate Communications

Cell: +44 7561 431 762

Email: ir@nordicnanovector.com

About Nordic Nanovector

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. Further information can be found at www.nordicnanovector.com.

This information is subject to a duty of disclosure pursuant to Section 5-12 of the Securities Trading Act.

 

http://www.netfonds.no/quotes/release.php?id=20190220.Cision.20190220:BIT:3476:0

[anon21766851]

Spent på prospekt. Juice, eller tørr affære?

[solb]

Betaling innen 8.mars og aksjene er straks på depoet.

[InVivo]

Alltid litt juice hvis man gidder å lese gjennom:

201902203476-1.pdf

[Nocturne]

Hvorfor? Kursen er jo under emikurs…

Får vente til 6. Mars og se om man skal tegne seg her da

[InVivo]

Store forhåpninger til ARCHER-1:

''The rationale for Archer-1 was provided by preclinical data recently published in the European
Journal of Haematology in July 201864. These data demonstrate that treatment with the
combination of Betalutin® and RTX significantly prolonged overall survival in a murine model of
NHL compared to treatment with either agent alone, possibly by reverting downregulation of
CD20 and resistance to RTX.

Should these effects be confirmed in Archer-1 and subsequent clinical trials, it could represent
a novel dual immunotherapy approach for the treatment of patients with 2L R/R FL. ‘’

[Hallakis]

Å lese gjennom punkt 2 om risk factors var hvertfall nitrist lesing stod side opp og side ned om alt som kan gjøre selskapet verdiløst

[anon21766851]

Det hagler med reklamasjoner til hengsleprodusenten som utstyrte oksefjøsen:

As of the date of this Prospectus, PARADIGME is open for patient enrolment at 67 (of 80-85)
clinical sites in 20 (of 20) countries, including the USA. The first patient was dosed in June 2018.

Alle land er oppe, med 67 sentere. Har noen mistet en sekk med solsikkefrø, eller lukter det bare fugl?

[MrSpecial]

Oppløftende info i forhold til åpne sites Fra prospektet side 64:

Edit: Du var hakket kjappere @anon21766851

[Hallakis]

Wtf!! Snart 70 sites åpen og protokollen godkjent i samtlige 20 land! Langt over hva folk her inne forventet, meg selv inkludert.

[anon21766851]

Men fundamentalt sett kunne vel NANO meldt denne senterstatusen. Innrullering er jo strengt tatt det største usikkerhetsmomentet jeg ser i NANO.

[Zuba]

Champagne problems in Nano , again!!

[eklof99]

“Over-subscription and subscription without Subscription Rights will be permitted”

Er dette grunnen til at de kjører rep. emi. til tross for at kursen er langt under? Mulig å tegne seg uten tegningsretter.

[InVivo]

As of the date of this Prospectus, PARADIGME is open for patient enrolment at 67 (of 80-85)
clinical sites in 20 (of 20) countries, including the USA. The first patient was dosed in June 2018.

Med 67 sentre åpne så burde det være mulig å klare 2 pasienter per senter pr år.
Bør jo sågar være mulig å få inn alle 130 pasientene i løpet av 2019.

I følge @Senior går jo rekrutteringen over all forventning!